 |
|
|
| |
Safety, Tolerability, and Antiviral Activity of the siRNA VIR-2218 in Combination With the Investigational Neutralizing Monoclonal Antibody VIR-3434 For the Treatment of Chronic Hepatitis B Virus Infection: Preliminary Results From the Phase 2 MARCH Trial
|
| |
| |
AASLD 2022 Nov 4-8
|
| |
|
|
|
|
|
